Aarhus University Seal

BRIEF INTRODUCTION TO ODIN

On this page you can find information about the ODIN network. If you have questions or comments you are of course welcome to contact us.

In brief, the Open Discovery Innovation Network (ODIN) is a five-year project at Aarhus University from 2024-2028. The Novo Nordisk Foundation (NNF) has awarded ODIN 180 M DKK to establish the network, facilitate co-creation of novel research projects and provide funding for the academic component of joint initiatives between academia and industrial partners from the pharma and biotech industries. 

ODIN’s open approach aims to provide a substrate and a catalyst for innovation: ODIN projects must be equal collaborations between academia and industry on the earliest stages of drug discovery and they must address real industrial research needs. ODIN projects must generate the building blocks necessary for developing new innovative therapeutics and diagnostics downstream - and they must share their data and results openly with the public to accelerate innovation.

Watch the video to the right for a 2-minute introduction to what ODIN is and why you should join us.

BRIEF INTRODUCTION TO ODIN

On this page you can find information about the ODIN network. If you have questions or comments you are of course welcome to contact us.

In brief, the Open Discovery Innovation Network (ODIN) is a five-year project at Aarhus University from 2024-2028. The Novo Nordisk Foundation (NNF) has awarded ODIN 180 M DKK to establish the network, facilitate co-creation of novel research projects and provide funding for the academic component of joint initiatives between academia and industrial partners from the pharma and biotech industries. 

ODIN’s open approach aims to provide a substrate and a catalyst for innovation: ODIN projects must be equal collaborations between academia and industry on the earliest stages of drug discovery and they must address real industrial research needs. ODIN projects must generate the building blocks necessary for developing new innovative therapeutics and diagnostics downstream - and they must share their data and results openly with the public to accelerate innovation.

Watch the video below for a 2-minute introduction to what ODIN is and why you should join us.


ABOUT THE ODIN PLATFORM


In this document you will get a brief overview of different aspects of the ODIN network: The ODIN model, why you should join the network, and introduction to the two call types in ODIN.

ODIN's governance structure consists of several organs including our Steering Group, the Project Review Committee as well as industrial and academic ambassadors. 

ODIN's Steering Group and Project Review Committee are governed by a set of principles laid out in these Governing Principles. They describe different principles such as consittution, decision-making and eligibilty.


Get to know the first funded ODIN projects - and  learn what both the academic researchers and industry have gained from the projects.

The Danish Centre for Studies in Research and Research Policy has conducted an impact assessment of the ODIN pilot project (2020-2023). You can read the full report right here or find an overview of the main points on the "Impact assessment" page.


ODIN CALL ROUNDS - THE NEXT ONE WILL BE ANNOUNCE IN FEBRUARY 2025


This document describes the phases of ODINs funding calls - from matchmaking and ideation over writing and reviewing to the funding decisions.

Here you can find the guidelines for the 2024 funding call in ODIN. Please note that the call guidelines might be changed slightly for the upcoming 2025 call round. It is therefore important that you make sure to download the 2025 guidelines, when they are available. They will be uploaded right here on the website and on our online platform.

Watch the 2024 ODIN information meeting (again). You will be introduced to the ODIN collaboration model as well as the 2024 call. You will also get an introduction to the type of projects that are suited for openness.


LEGAL DOCUMENTS IN ODIN


Here you can read ODIN's Framework Agreement, which has been negotiated by the core partners in ODIN. Among other things, the Agreement describes the legal framework of ODIN, including the open collaboration model and ODIN's governing organs.

The fully signed Framework Agreement includes Accession Documents signed by Roche and PentaBase.

In this document, you can read how ODIN processes your data, when handling your funding application.

The Project Agreement is to be entered by all project participants before starting an ODIN project. The agreement is non-negotiable, as the terms will be defined in collaboration between the core partners before the launch of ODIN calls.


Here you can read the Terms & Conditions for using ODIN's WorldLabs platform. You will also find a description on how we carry out random checks at the WorldLabs platform.

External reviewers of funding applications in ODIN, will be bound by the ODIN Consultancy Agreement. Here you can find a template for the Consultancy Agreement.


WATCH THE ANNOUNCEMENT VIDEO

Here you can watch the video released by the Novo Nordisk Foundation for the announcement of the renewal of ODIN.

In the video, you can meet both executives from the Novo Nordisk Foundation, industry and universities as well as researchers who participated in ODIN.



ABOUT ODIN

We unite right minds from industry and academia so that they can jointly create need-driven research projects - and pave the way for innovative new treatments in the future. Through competitive funding calls, we fund the best projects ideas. Although companies cannot receive funding, it is free of charge to join.

The 5-year platform is sponsored by the Novo Nordisk Foundation with 180 M DKK from 2024-2028.

CONTACT ODIN

You are always welcome to reach out if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.

Although we're spanning five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 121, blg 1521-216.